×




The Challenge of Access to Oncology Drugs in Canada Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for The Challenge of Access to Oncology Drugs in Canada case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. The Challenge of Access to Oncology Drugs in Canada case study is a Harvard Business School (HBR) case study written by Gregory S. Zaric, Chander Sehgal. The The Challenge of Access to Oncology Drugs in Canada (referred as “Drug Cost” from here on) case study provides evaluation & decision scenario in field of Technology & Operations. It also touches upon business topics such as - Value proposition, .

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of The Challenge of Access to Oncology Drugs in Canada Case Study


In recent years, many countries with publicly funded healthcare have started using cost-effectiveness analysis (CEA) along with review of clinical data as a tool to assess the overall benefit of a new drug to the society and set priorities with regards to health care budget. Cost effectiveness was formally incorporated into the Ontario drug review system in 1993 and the Canadian drug-review system in 2003. The issue of using cost effectiveness has become increasingly contentious in recent years: some newly approved cancer drugs cost $3,000 to $6,000 or more for one treatment cycle, but their high prices means that they were often classified as being not cost effective. This note reviews many of the competing interests in debates over drug funding and dilemmas about healthcare financing decisions in the presence of limited budgets.


Case Authors : Gregory S. Zaric, Chander Sehgal

Topic : Technology & Operations

Related Areas :




Calculating Net Present Value (NPV) at 6% for The Challenge of Access to Oncology Drugs in Canada Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10024015) -10024015 - -
Year 1 3444231 -6579784 3444231 0.9434 3249275
Year 2 3973389 -2606395 7417620 0.89 3536302
Year 3 3937769 1331374 11355389 0.8396 3306227
Year 4 3233651 4565025 14589040 0.7921 2561354
TOTAL 14589040 12653158




The Net Present Value at 6% discount rate is 2629143

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Internal Rate of Return
2. Profitability Index
3. Net Present Value
4. Payback Period

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Drug Cost shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Drug Cost have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.






Formula and Steps to Calculate Net Present Value (NPV) of The Challenge of Access to Oncology Drugs in Canada

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Technology & Operations Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Drug Cost often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Drug Cost needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10024015) -10024015 - -
Year 1 3444231 -6579784 3444231 0.8696 2994983
Year 2 3973389 -2606395 7417620 0.7561 3004453
Year 3 3937769 1331374 11355389 0.6575 2589147
Year 4 3233651 4565025 14589040 0.5718 1848850
TOTAL 10437434


The Net NPV after 4 years is 413419

(10437434 - 10024015 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10024015) -10024015 - -
Year 1 3444231 -6579784 3444231 0.8333 2870193
Year 2 3973389 -2606395 7417620 0.6944 2759298
Year 3 3937769 1331374 11355389 0.5787 2278802
Year 4 3233651 4565025 14589040 0.4823 1559438
TOTAL 9467730


The Net NPV after 4 years is -556285

At 20% discount rate the NPV is negative (9467730 - 10024015 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Drug Cost to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Drug Cost has a NPV value higher than Zero then finance managers at Drug Cost can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Drug Cost, then the stock price of the Drug Cost should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Drug Cost should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of The Challenge of Access to Oncology Drugs in Canada

References & Further Readings

Gregory S. Zaric, Chander Sehgal (2018), "The Challenge of Access to Oncology Drugs in Canada Harvard Business Review Case Study. Published by HBR Publications.


Sbs Media Hold SWOT Analysis / TOWS Matrix

Services , Broadcasting & Cable TV


NuVista Energy SWOT Analysis / TOWS Matrix

Energy , Oil & Gas Operations


Indal Aluminium SWOT Analysis / TOWS Matrix

Basic Materials , Metal Mining


Pebblebrook Hotel SWOT Analysis / TOWS Matrix

Services , Real Estate Operations


Ovid Therapeutics SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs